HIV Envelope Protein gp41
"HIV Envelope Protein gp41" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING.
Descriptor ID |
D015700
|
MeSH Number(s) |
D12.776.543.512.500.330 D12.776.964.775.325.164.200 D12.776.964.775.562.500.200 D12.776.964.970.880.325.164.200 D12.776.964.970.880.910.330 D23.050.327.520.330
|
Concept/Terms |
HIV Envelope Protein gp41- HIV Envelope Protein gp41
- Envelope Protein gp41, HIV
- HTLV-III gp41
- gp41(HIV)
- HIV Transmembrane Protein gp41
- env Protein gp41, HIV
- gp41 Envelope Protein, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Envelope Protein gp41".
Below are MeSH descriptors whose meaning is more specific than "HIV Envelope Protein gp41".
This graph shows the total number of publications written about "HIV Envelope Protein gp41" by people in this website by year, and whether "HIV Envelope Protein gp41" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 1 | 0 | 1 | 2007 | 0 | 1 | 1 | 2015 | 1 | 0 | 1 | 2020 | 1 | 0 | 1 | 2021 | 2 | 0 | 2 | 2022 | 0 | 2 | 2 | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Envelope Protein gp41" by people in Profiles.
-
Kim S, Radford CE, Xu D, Zhong J, Do J, Pham DM, Travisano KA, Filsinger Interrante MV, Bruun TUJ, Rezek V, Wilder B, Palomares M, Seaman MS, Kitchen SG, Bloom JD, Kim PS. A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning. Nat Commun. 2025 May 18; 16(1):4617.
-
Kim S, Filsinger Interrante MV, Kim PS. Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies. J Virol. 2023 01 31; 97(1):e0164722.
-
Fernandez-de C?spedes MV, Hoffman HK, Carter H, Simons LM, Naing L, Ablan SD, Scheiblin DA, Hultquist JF, van Engelenburg SB, Freed EO. Rab11-FIP1C Is Dispensable for HIV-1 Replication in Primary CD4+ T Cells, but Its Role Is Cell Type Dependent in Immortalized Human T-Cell Lines. J Virol. 2022 12 14; 96(23):e0087622.
-
Rubio AA, Filsinger Interrante MV, Bell BN, Brown CL, Bruun TUJ, LaBranche CC, Montefiori DC, Kim PS. A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. J Virol. 2021 07 12; 95(15):e0235020.
-
Montefiori DC, Filsinger Interrante MV, Bell BN, Rubio AA, Joyce JG, Shiver JW, LaBranche CC, Kim PS. The high-affinity immunoglobulin receptor Fc?RI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat. Proc Natl Acad Sci U S A. 2021 01 19; 118(3).
-
Fernandez MV, Hoffman HK, Pezeshkian N, Tedbury PR, van Engelenburg SB, Freed EO. Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail. J Virol. 2020 11 09; 94(23).
-
Redd AD, Wendel SK, Longosz AF, Fogel JM, Dadabhai S, Kumwenda N, Sun J, Walker MP, Bruno D, Martens C, Eshleman SH, Porcella SF, Quinn TC, Taha TE. Evaluation of postpartum HIV superinfection and mother-to-child transmission. AIDS. 2015 Jul 31; 29(12):1567-73.
-
Chen J, Kovacs JM, Peng H, Rits-Volloch S, Lu J, Park D, Zablowsky E, Seaman MS, Chen B. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science. 2015 Jul 10; 349(6244):191-5.
-
Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 07; 370(9581):39-48.
-
Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006; 11(5):619-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|